Only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for preuviously treated patients in this setting TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has received
BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process PRINCETON, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BLUE #BMS—Bristol
Application Based on First Contemporary Outcomes Study Focused Exclusively on Chronic Heart Failure Patient Population Following a Worsening Event KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug